James C Yang

List of Publications by Year
in descending order

		70961	102304
70 papers	26,394 citations	41 h-index	66 g-index

70 all docs	70 docs citations	70 times ranked	19048 citing authors

#	Article	IF	Citations
1	Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. Journal of Clinical Oncology, 2022, 40, 1741-1754.	0.8	65
2	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science, 2022, 375, 877-884.	6.0	156
3	A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell, 2022, 40, 479-493.e6.	7.7	64
4	Neoantigen Identification and Response to Adoptive Cell Transfer in Antiâ€“PD-1 NaÃ¯ve and Experienced Patients with Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 3042-3052.	3.2	18
5	Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience. Leukemia and Lymphoma, 2022, 63, 2469-2473.	0.6	6
6	Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptorâ€"Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. Cancer Immunology Research, 2022, 10, 932-946.	1.6	52
7	Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma. Molecular and Cellular Proteomics, 2021, 20, 100136.	2.5	19
8	Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma. Clinical Cancer Research, 2021, 27, 5289-5298.	3.2	39
9	Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. Blood, 2021, 138, 3837-3837.	0.6	8
10	The ongoing mystery of renal cell cancer. Cell Reports Medicine, 2021, 2, 100445.	3.3	0
11	Mutated RAS: Targeting the â€œUntargetableâ€•with T Cells. Clinical Cancer Research, 2020, 26, 537-544.	3.2	25
12	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 2020, 38, 3805-3815.	0.8	129
13	Novel MHC-Independent Î±Î²TCRs Specific for CD48, CD102, and CD155 Self-Proteins and Their Selection in the Thymus. Frontiers in Immunology, 2020, 11, 1216.	2.2	3
14	Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain. Blood, 2020, 136, 50-51.	0.6	14
15	Adoptive T-Cell Therapy for Solid Malignancies. Surgical Oncology Clinics of North America, 2019, 28, 465-479.	0.6	10
16	CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nature Communications, 2019, 10, 4016.	5.8	208
17	Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. Journal of Clinical Investigation, 2019, 129, 4992-5004.	3.9	107
18	Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. Journal of Immunotherapy, 2018, 41, 241-247.	1.2	40

#	Article	IF	Citations
19	CD70, a novel target of CAR T-cell therapy for gliomas. Neuro-Oncology, 2018, 20, 55-65.	0.6	122
20	Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 947-951.	0.7	26
21	Debugging the Black Box. Cancer Discovery, 2017, 7, 250-251.	7.7	0
22	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 792-802.	5.1	203
23	Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor TÂCell Therapy. Molecular Therapy, 2017, 25, 2245-2253.	3.7	227
24	Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clinical Cancer Research, 2017, 23, 2267-2276.	3.2	64
25	Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. Annals of Surgical Oncology, 2017, 24, 135-141.	0.7	24
26	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an â€œexceptional responderâ€•lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Journal of Physical Education and Sports Management, 2016, 2, a001263.	0.5	18
27	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2016, 34, 2389-2397.	0.8	293
28	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nature Medicine, 2016, 22, 433-438.	15.2	721
29	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunology Research, 2016, 4, 204-214.	1.6	175
30	The Immunotherapy Roadmap. Clinical Cancer Research, 2016, 22, 275-276.	3.2	2
31	Toxicities Associated With Adoptive T-Cell Transfer for Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 506-509.	1.0	38
32	Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research, 2015, 21, 2278-2288.	3.2	310
33	A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1â€"Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research, 2015, 21, 1019-1027.	3.2	677
34	Landscape of Tumor Antigens in T Cell Immunotherapy. Journal of Immunology, 2015, 195, 5117-5122.	0.4	124
35	Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. Clinical Cancer Research, 2015, 21, 534-543.	3.2	47
36	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. Journal of Clinical Investigation, 2014, 124, 2246-2259.	3.9	892

#	Article	IF	Citations
37	MSLT-Iâ€"response of clinical trial investigators. Nature Reviews Clinical Oncology, 2014, 11, 680-680.	12.5	1
38	Why is sentinel lymph node biopsy 'standard of care' for melanoma?. Nature Reviews Clinical Oncology, 2014, 11, 245-246.	12.5	16
39	Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. Clinical Cancer Research, 2014, 20, 3401-3410.	3.2	364
40	The adoptive transfer of cultured T cells for patients with metastatic melanoma. Clinics in Dermatology, 2013, 31, 209-219.	0.8	5
41	Melanoma Vaccines. Cancer Journal (Sudbury, Mass), 2011, 17, 277-282.	1.0	10
42	Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research, 2011, 17, 4550-4557.	3.2	1,823
43	Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology, 2011, 29, 917-924.	0.8	1,427
44	T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Molecular Therapy, 2011, 19, 620-626.	3.7	857
45	Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells. Journal of Immunotherapy, 2010, 33, 956-964.	1.2	174
46	Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Molecular Therapy, 2010, 18, 843-851.	3.7	2,079
47	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 2009, 114, 535-546.	0.6	1,280
48	Vitespen: a vaccine for renal cancer?. Lancet, The, 2008, 372, 92-93.	6.3	13
49	Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology, 2008, 26, 5233-5239.	0.8	1,210
50	Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis. Journal of Immunotherapy, 2007, 30, 825-830.	1.2	656
51	Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science, 2006, 314, 126-129.	6.0	2,352
52	Treatment of Oligometastases After Successful Immunotherapy. Seminars in Radiation Oncology, 2006, 16, 131-135.	1.0	28
53	Immunotherapy for Renal Cell Cancer. Journal of Clinical Oncology, 2006, 24, 5576-5583.	0.8	105
54	Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma. Journal of Clinical Oncology, 2005, 23, 2346-2357.	0.8	1,452

#	Article	IF	Citations
55	Bevacizumab for Patients with Metastatic Renal Cancer: Fig. 1.. Clinical Cancer Research, 2004, 10, 6367S-6370S.	3.2	125
56	Reply to "Cancer vaccines: pessimism in check". Nature Medicine, 2004, 10, 1279-1280.	15.2	19
57	A Randomized Trial of Bevacizumab, an Antiâ€"Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. New England Journal of Medicine, 2003, 349, 427-434.	13.9	2,640
58	A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma. Journal of Immunotherapy, 2002, 25, 243-251.	1.2	326
59	Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer, 2001, 91, 1525-1529.	2.0	90
60	A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-Î³ chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nature Medicine, 1998, 4, 168-172.	15.2	63
61	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 1998, 4, 321-327.	15.2	1,693
62	Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells. Annals of Surgical Oncology, 1996, 3, 67-73.	0.7	12
63	The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer, 1995, 75, 1030-1037.	2.0	50
64	The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. Cancer, 1995, 76, 687-694.	2.0	79
65	The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. , 1995, 76, 687.		1
66	Localization of111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer, 1994, 73, 1731-1737.	2.0	204
67	Localization of 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. , 1994, 73, 1731.		1
68	Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer, 1992, 69, 1850-1855.	2.0	61
69	In Vivo Distribution of Adoptively Transferred Indium- 111- Labeled Tumor Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Patients With Metastatic Melanoma. Journal of the National Cancer Institute, 1989, 81, 1709-1717.	3.0	176
70	Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. New England Journal of Medicine, 1988, 319, 1676-1680.	13.9	2,076